Perioperative Targeted Immunotherapy Combined With Transarterial Chemoembolization Improves Survival in Borderline Resectable Hepatocellular Carcinoma
International Journal of Cancer · 01.09.2026 · 159 (5) · 1248-1259
DOI: 10.1002/ijc.70495 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 21.04.2026. Verfasst von Jianwei Liu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatic Surgery II, Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital), Shanghai, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Chemoembolization, Therapeutic, Immunotherapy. Die Arbeit nennt 29 Literaturangaben. Gefördert von: the Scientific research project of Shanghai Municipal Health Commission, Tengfei Engineering Talent Cultivation Program of Third Affiliated Hospital of Naval Medical University, Naval Medical University Third Affiliated Hospital Departmental Project in 2025-Clinical Research Cultivation Program.
Abstract (Originalsprache)
To compare targeted immunotherapy plus adjuvant transarterial chemoembolization (TACE) versus TACE alone in patients with borderline resectable hepatocellular carcinoma (BR‐HCC). 297 BR‐HCC patients who underwent liver resection were included. Among them, 86 patients received perioperative targeted immunotherapy combined with adjuvant TACE (combination therapy group, which included neoadjuvant therapy and adjuvant therapy), while 211 received adjuvant TACE alone (TACE‐only group). After propensity score matching (PSM), the combination therapy group demonstrated significantly improved 1‐, 3‐, and 5‐year OS rates (90.7%, 66.0%, and 58.1%, respectively) compared to the TACE‐only group (86.0%, 55.2%, and 35.1%; p = 0.013). Similarly, 1‐, 3‐, and 5‐year RFS rates were higher in the combination therapy group (66.3%, 36.9%, and 31.0%) than in the TACE‐only group (55.8%, 23.1%, and 13.8%; p = 0.007). Multivariable analysis confirmed that combination therapy was an independent protective factor for both OS (HR: 0.619, 95% CI: 0.389–0.983) and RFS (0.665, 0.469–0.944). Subgroup analysis showed that in adjuvant therapy and TACE‐only, TACE‐only was an independent risk factor for OS (1.986, 1.105–3.566) and RFS (1.831, 1.132–2.962) compared with adjuvant therapy (receiving postoperative adjuvant targeted immunotherapy and TACE). Further analysis showed that in the combination therapy subgroup, adjuvant therapy was an independent risk factor for OS (2.701, 1.171–6.230) and RFS (2.051, 1.125–3.739) compared to neoadjuvant therapy (receiving both preoperative neoadjuvant and postoperative adjuvant targeted immunotherapy and TACE). No significant difference in complications/AEs following surgery/TACE was observed between the two groups. Perioperative targeted immunotherapy combined with adjuvant TACE significantly improves OS and RFS in BR‐HCC patients without increasing the incidence of complications/AEs following surgery/TACE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hepatic Surgery II, Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital), Shanghai, China.
- Department of Hepatic Surgery IV, Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital), Shanghai, China.
- Department of General Surgery, Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital), Shanghai, China.
- Department of Gastroenterology, Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital), Shanghai, China.
- Department of Pathology, Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital), Shanghai, China.
ORCID-Profile: Jianwei Liu, Ming Tang, Kui Wang, Feng Shen, Yong Xia
Förderung
- the Scientific research project of Shanghai Municipal Health Commission
- Tengfei Engineering Talent Cultivation Program of Third Affiliated Hospital of Naval Medical University
- Naval Medical University Third Affiliated Hospital Departmental Project in 2025-Clinical Research Cultivation Program
- Shanghai Clinical Cohort Project-Reserve Clinical Cohort
- Jiading District Health Commission 2025 Scientific Research Projects
- 2025 Shanghai Oriental Talent Program - Top-notch Project
Zitieren
APA
Liu, J., Tang, M., Xuan, J., Tang, T., Zhong, Y., Ma, J., Liu, L., Yang, Z., Wei, W., Wang, H., Wang, K., Shen, F., & Xia, Y. (2026). Perioperative Targeted Immunotherapy Combined With Transarterial Chemoembolization Improves Survival in Borderline Resectable Hepatocellular Carcinoma. International Journal of Cancer, 159(5), 1248-1259. https://doi.org/10.1002/ijc.70495
Vancouver
Liu J, Tang M, Xuan J, Tang T, Zhong Y, Ma J, et al. Perioperative Targeted Immunotherapy Combined With Transarterial Chemoembolization Improves Survival in Borderline Resectable Hepatocellular Carcinoma. International Journal of Cancer. 2026;159(5):1248-1259. doi:10.1002/ijc.70495
BibTeX
@article{Liu2026,
author = {Liu, Jianwei and Tang, Ming and Xuan, Jianbing and Tang, Tianle and Zhong, Yameng and Ma, Junyong and Liu, Liu and Yang, Zhishi and Wei, Wenxin and Wang, Han and Wang, Kui and Shen, Feng and Xia, Yong},
title = {Perioperative Targeted Immunotherapy Combined With Transarterial Chemoembolization Improves Survival in Borderline Resectable Hepatocellular Carcinoma},
journal = {International Journal of Cancer},
year = {2026},
volume = {159},
number = {5},
pages = {1248--1259},
doi = {10.1002/ijc.70495}
}
EUVIMED